People News: Biogen Idec and Nektar Therapeutics

Share this article:
Caroline Dorsa, a former Merck exec, was appointed to Biogen Idec's board of directors. Dorsa, previously SVP global human health, strategy and integration at Merck, is currently EVP and chief financial officer at Public Service Enterprise Group. Her appointment, to fill a vacancy, comes days after the announcement that president and CEO James Mullen would retire from Biogen Idec in June.

Stephen K. Doberstein, PhD was named SVP, chief scientific officer at Nektar Therapeutics, reporting to CEO Howard Robin. Dr. Doberstein, 50, joins Nektar from Xoma, where he was VP research, responsible for directing discovery and development of drug candidates.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions